| Amphastar Pharmaceuticals: Navigating Through An Inflection Year |
Amphastar Pharmaceuticals posted Q1 results last week that beat the bottom-line consensus. The stock appears cheap at under eight times forward earnings, but the company is going through an 'inflection year' with flat revenue growth and declining profits. Growth should return in 2026 thanks to upcoming product launches. Is the stock cheap enough to buy the recent dip in the shares? |
seekingalpha.com |
2025-05-11 15:32:11 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference |
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 9, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 2025 Bank of America Health Care Conference on Wednesday, May 14th, 2025, at 1:40 pm PT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. |
accessnewswire.com |
2025-05-09 10:00:00 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics |
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-08 00:30:37 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals Inc. (AMPH) Q1 2025 Earnings Call Transcript |
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants David Amsellem - Piper Sandler Cerena Chen - Wells Fargo Jason Gerberry - Bank of America Ekaterina Knyazkova - JPMorgan Operator Greetings and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-07 23:20:15 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates |
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.04 per share a year ago. |
zacks.com |
2025-05-07 22:41:22 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 |
Reports Net Revenues of $170.5 Million for the Three Months Ended March 31, 2025 RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2025. First Quarter Highlights Net revenues of $170.5 million for the first quarter GAAP net income of $25.3 million, or $0.51 per share, for the first quarter Adjusted non-GAAP net income of $36.9 million, or $0.74 per share, for the first quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are confident in the potential of our portfolio, particularly with the growth of BAQSIMI® and Primatene MIST®, and the promising pipeline of biosimilars and proprietary products. |
accessnewswire.com |
2025-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock? |
Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately. |
zacks.com |
2025-05-01 20:10:35 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025 |
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. |
accessnewswire.com |
2025-04-30 10:00:00 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference |
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th, 2025, at 1:30 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. |
accessnewswire.com |
2025-04-03 10:00:00 |
Czytaj oryginał (ang.) |
| International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award |
Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that International Medication Systems, Ltd. ("IMS"), a subsidiary of Amphastar Pharmaceuticals, Inc. ("Amphastar") received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration ("FDA"). |
accessnewswire.com |
2025-03-28 08:00:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for March 24th |
AVNS, AIRS and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2025. |
zacks.com |
2025-03-24 08:30:22 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference |
RANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations will be presenting at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, 2025, at 10:30 am ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. |
accessnewswire.com |
2025-03-05 08:00:00 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - AMPH |
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. |
accessnewswire.com |
2025-03-04 09:30:00 |
Czytaj oryginał (ang.) |
| AMPH ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Amphastar Pharmaceuticals, Inc. Shareholders Who Lost Money |
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. |
accessnewswire.com |
2025-03-03 09:30:00 |
Czytaj oryginał (ang.) |
| Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds |
On Thursday, Amphastar Pharmaceuticals Inc. AMPH reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the consensus of 94 cents. |
benzinga.com |
2025-02-28 16:15:52 |
Czytaj oryginał (ang.) |
| Amphastar: Earnings Miss, Margins Drop |
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results. |
fool.com |
2025-02-28 11:56:11 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals, Inc. Being Investigated on Behalf of Amphastar Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details |
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. |
accessnewswire.com |
2025-02-28 09:30:00 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals Inc. (AMPH) Q4 2024 Earnings Call Transcript |
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants Jason Gerberry - Bank of America Cerena Chen - Wells Fargo Ekaterina Knyazkova - JPMorgan David Amsellem - Piper Sandler Serge Belanger - Needham & Company Operator Greetings and welcome to the Amphastar Pharmaceuticals Fourth Quarter Earnings Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-02-28 01:04:02 |
Czytaj oryginał (ang.) |
| Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-27 21:30:29 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates |
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.92 per share, missing the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.88 per share a year ago. |
zacks.com |
2025-02-27 21:15:31 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024 |
Reports Net Revenues of $186.5 Million for the Three Months Ended December 31, 2024 RANCHO CUCAMONGA, CA / ACCESS Newswire / February 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full year ended December 31, 2024. Fourth quarter Highlights Net revenues of $186.5 million for the fourth quarter GAAP net income of $38.0 million, or $0.74 per share, for the fourth quarter Adjusted non-GAAP net income of $47.2 million, or $0.92 per share, for the fourth quarter Full Year Highlights Net revenues of $732.0 million for the fiscal year GAAP net income of $159.5 million, or $3.06 per share, for the fiscal year Adjusted non-GAAP net income of $200.8 million, or $3.86 per share, for the fiscal year Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are incredibly proud that in 2024, we exceeded our long-term goal of achieving $100 million in annual sales for Primatene MIST®, and we look forward to continuing to grow the brand. |
accessnewswire.com |
2025-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| AMPH STOCK ALERT: Levi & Korsinsky Notifies Amphastar Pharmaceuticals, Inc. Investors of an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. |
accessnewswire.com |
2025-02-27 09:30:00 |
Czytaj oryginał (ang.) |
| AMPH STOCK ALERT: Levi & Korsinsky Notifies Amphastar Pharmaceuticals, Inc. Investors of an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. |
accessnewswire.com |
2025-02-26 09:30:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Announces an Investigation on Behalf of Amphastar Pharmaceuticals, Inc. (AMPH) Shareholders Who May Have Been Affected by Fraud |
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. |
accessnewswire.com |
2025-02-25 09:30:00 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals, Inc. (AMPH) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates |
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. |
accessnewswire.com |
2025-02-24 09:30:00 |
Czytaj oryginał (ang.) |
| Investors who Lost Money on Amphastar Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - AMPH |
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. |
accessnewswire.com |
2025-02-21 09:30:00 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025 |
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Fourth quarter of 2024 ended December 31, 2024, after the market closes on Thursday, February 27, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. |
accessnewswire.com |
2025-02-20 18:05:00 |
Czytaj oryginał (ang.) |
| ATTENTION AMPH SHAREHOLDERS: Investors who lost money on Amphastar Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation |
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. |
accessnewswire.com |
2025-02-20 09:25:00 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals: A Gradual Strategy |
Amphastar Pharmaceuticals has a growth model based on organic growth and acquisitions, though competition and patent expirations pose risks. Financially, Amphastar has a strong revenue trend but faces potential growth slowdowns, especially in 2025. A fair value estimate derived from a DCF model and backed by a comparison with peers is $43.24, which suggests a 40% upside. |
seekingalpha.com |
2025-02-19 15:09:18 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - AMPH |
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. |
accessnewswire.com |
2025-02-19 09:25:00 |
Czytaj oryginał (ang.) |
| Lost Money on Amphastar Pharmaceuticals, Inc. (AMPH)? Contact Levi & Korsinsky Regarding an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. |
accessnewswire.com |
2025-02-18 09:30:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Investigates Possible Securities Fraud Violations by Amphastar Pharmaceuticals, Inc. (AMPH) |
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. |
accessnewswire.com |
2025-02-14 19:00:00 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. |
accesswire.com |
2025-01-08 08:00:00 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals: Cheap With Caveats |
Amphastar Pharmaceuticals' stock has declined over 25% since early November, despite solid earnings and sales growth, presenting a potential buying opportunity. Q3 results were impacted somewhat by the effects of Hurricane Helene, after easily exceeding top and bottom-line expectations in Q2. The stock is cheap on a P/E basis, but there are some caveats, including patent expiration in early 2026 on a key product. |
seekingalpha.com |
2025-01-03 14:48:33 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for January 2nd |
AGCO, AMPH and ASC have been added to the Zacks Rank #24 (Strong Sell) List on January 2, 2024. |
zacks.com |
2025-01-02 08:56:09 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for December 31st |
AGL, AMPH and CR have been added to the Zacks Rank #24 (Strong Sell) List on December 31, 2024. |
zacks.com |
2024-12-31 08:51:19 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference |
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. |
accesswire.com |
2024-11-26 18:05:00 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference |
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. |
accesswire.com |
2024-11-13 18:05:00 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Transcript |
Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-11-06 23:12:07 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings |
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2024-11-06 21:00:30 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals (AMPH) Lags Q3 Earnings and Revenue Estimates |
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.15 per share a year ago. |
zacks.com |
2024-11-06 20:36:15 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024 |
Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2024. Third quarter Highlights Net revenues of $191.2 million for the third quarter GAAP net income of $40.4 million, or $0.78 per share, for the third quarter Adjusted non-GAAP net income of $49.6 million, or $0.96 per share, for the third quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Amphastar has continued its growth this quarter, highlighted by sales, particularly from BAQSIMI®, which has become a cornerstone in our portfolio, and Primatene MIST®, which is trending toward our goal of $100 million in sales per year. |
accesswire.com |
2024-11-06 18:05:00 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy? |
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-30 13:07:07 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024 |
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2024 ended September 30, 2024, after the market closes on Wednesday, November 6, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. |
accesswire.com |
2024-10-29 08:00:00 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-10-25 14:45:28 |
Czytaj oryginał (ang.) |
| Will Amphastar (AMPH) Beat Estimates Again in Its Next Earnings Report? |
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2024-10-18 17:16:20 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals Inc (AMPH) Trading Down 3.54% on Oct 2 |
Shares of Amphastar Pharmaceuticals Inc (AMPH, Financial) fell 3.54% in mid-day trading on Oct 2. The stock reached an intraday low of $46.58, before recovering slightly to $46.64, down from its previous close of $48.35. |
gurufocus.com |
2024-10-02 16:08:03 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals Offers Interesting Growth And Income Prospects |
Amphastar Pharmaceuticals shows promising growth potential with its diverse product offerings, including the nasally administered glucagon treatment BAQSIMI and the over-the-counter inhalant Primatene MIST. The company's solid balance sheet, with a current ratio of 3.52 and manageable debt levels, provides flexibility to navigate market changes. Risks include reliance on single-source supplies, dependency on Lilly for BAQSIMI manufacturing, and the impact of reference brand demand on generic products. |
seekingalpha.com |
2024-09-13 11:20:48 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference |
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. |
accesswire.com |
2024-08-28 20:10:00 |
Czytaj oryginał (ang.) |
| 6 Beaten Down Stocks Rated Buy (SA Quant) |
The three-week market selloff sparked by recession fears was led by plunging tech, cyclical, industrial, and energy stocks. High-quality stocks clobbered in the past 30 days, and others beaten down in the past year offer potential buying opportunities. We identified 6 stocks down by double digits within the last year with Buy or Strong Buy Quant Ratings, high forward growth metrics, and attractive valuations. |
seekingalpha.com |
2024-08-19 09:00:00 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2024 Earnings Call Transcript |
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer Tony Marrs - Executive Vice President, Regulatory Affairs and Clinical Operations Conference Call Participants Ekaterina Knyazkova - JPMorgan David Amsellem - Piper Sandler Jason Gerberry - Bank of America Tim Chiang - Capital One Serge Belanger - Needham & Company Glen Santangelo - Jefferies Operator Greetings, and welcome to the Amphastar Pharmaceuticals Second Quarter Earnings Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-08-09 23:47:06 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics |
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-08-08 00:36:18 |
Czytaj oryginał (ang.) |
| Amphastar Pharmaceuticals (AMPH) Tops Q2 Earnings and Revenue Estimates |
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.65 per share a year ago. |
zacks.com |
2024-08-07 22:30:42 |
Czytaj oryginał (ang.) |